Clinic
Yukon-Kuskokwim Health Corporation
Yukon-Kuskokwim Health Corporation was paid $205.26M by Medicaid between Jan 2018 and Dec 2024, across 290 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 8.3% of everything it billed.
33Billing provider infoYUKON-KUSKOKWIM HEALTH CORPORATION
BETHEL, AK 99559
BETHEL, AK 99559
33aNPI1063567691assigned 01/24/2007
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$205.26M
24GClaims1,205,315
24DCodes billed290
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Alaska
Rank by total paid#1 of 17
Median peer was paid$304K
This provider vs. median676×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 195,126 | $25.65M | |
| 2019 | 180,551 | $26.32M | |
| 2020 | 132,874 | $21.10M | |
| 2021 | 153,137 | $25.58M | |
| 2022 | 177,362 | $34.28M | |
| 2023 | 194,689 | $34.29M | |
| 2024incomplete | 171,576 | $38.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.3% | 99,901 | 48,240 | $16.94M |
| 87070 | 8.0% | 33,699 | 31,150 | $16.37M | |
| 80053 | Comprehensive metabolic panel | 7.6% | 32,632 | 29,387 | $15.64M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.6% | 92,792 | 40,474 | $11.56M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.0% | 38,913 | 36,035 | $10.22M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 4.9% | 27,347 | 26,742 | $10.03M |
| 81001 | 4.5% | 30,654 | 26,970 | $9.33M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 35,233 | 15,908 | $8.30M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.9% | 9,400 | 7,726 | $5.95M |
| 36415 | Collection of venous blood by venipuncture | 2.7% | 11,299 | 9,500 | $5.61M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.6% | 62,438 | 30,216 | $5.37M |
| 71046 | Radiologic examination, chest; 2 views | 2.3% | 32,611 | 15,314 | $4.73M |
278 more codes
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.2% | 25,191 | $4.47M |
| 80076 | 2.0% | 7,402 | $4.16M | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.8% | 7,770 | $3.77M |
| 86580 | 1.8% | 6,583 | $3.73M | |
| 99442 | 1.8% | 5,430 | $3.60M | |
| 99443 | 1.3% | 4,061 | $2.68M | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.3% | 6,612 | $2.67M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 8,356 | $2.23M |
| 80061 | Lipid panel | 1.0% | 11,863 | $2.11M |
| 86480 | 1.0% | 8,107 | $2.11M | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 10,057 | $2.03M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,445 | $1.61M |
| 85027 | <1% | 10,012 | $1.41M | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,707 | $1.41M |
| 99441 | <1% | 2,062 | $1.38M | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,893 | $1.34M |
| 87631 | <1% | 3,656 | $1.34M | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 7,887 | $1.30M |
| 81025 | <1% | 12,686 | $1.28M | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,926 | $1.27M |
| 73130 | <1% | 5,169 | $1.25M | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13,694 | $1.23M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,181 | $1.12M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 44,017 | $1.10M |
| 99241 | <1% | 1,726 | $1.03M | |
| 99284 | Emergency room visit (serious) | <1% | 41,705 | $1.00M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,562 | $900K |
| 86803 | <1% | 6,473 | $891K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,818 | $847K |
| 86703 | <1% | 12,328 | $799K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 1,058 | $782K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 1,471 | $711K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,613 | $702K |
| 73562 | <1% | 2,849 | $701K | |
| 82950 | <1% | 2,741 | $677K | |
| 84702 | <1% | 4,003 | $675K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 3,525 | $669K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,922 | $656K |
| 73610 | <1% | 2,733 | $649K | |
| 85018 | <1% | 1,611 | $644K | |
| 73630 | <1% | 2,622 | $624K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 5,545 | $624K |
| 86592 | <1% | 4,856 | $615K | |
| 82105 | <1% | 1,670 | $609K | |
| 80074 | <1% | 2,234 | $573K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,761 | $560K |
| 92567 | <1% | 2,607 | $546K | |
| 82728 | <1% | 4,090 | $539K | |
| 83520 | <1% | 2,668 | $528K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 791 | $515K |
| 73030 | <1% | 2,323 | $498K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 4,606 | $485K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 4,772 | $479K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 649 | $478K |
| 82607 | <1% | 2,558 | $476K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,125 | $475K |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 980 | $470K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,808 | $465K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 3,431 | $450K |
| 84439 | <1% | 4,039 | $449K | |
| 85652 | <1% | 2,866 | $437K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 2,690 | $423K |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 994 | $417K |
| H2010 | Comprehensive medication services, per 15 minutes | <1% | 672 | $397K |
| 76801 | <1% | 5,345 | $391K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,040 | $379K |
| 90632 | <1% | 429 | $356K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 5,236 | $347K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,007 | $343K |
| 73110 | <1% | 1,482 | $342K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,842 | $337K |
| 92557 | <1% | 540 | $318K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,985 | $295K |
| 92553 | <1% | 391 | $293K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,788 | $289K |
| 87077 | <1% | 4,455 | $283K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,233 | $274K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 11,591 | $266K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 11,065 | $232K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,868 | $215K |
| 82043 | <1% | 2,563 | $188K | |
| 73140 | <1% | 673 | $181K | |
| 73090 | <1% | 774 | $168K | |
| 73000 | <1% | 507 | $163K | |
| 76830 | Ultrasound, transvaginal | <1% | 990 | $149K |
| 73590 | <1% | 627 | $144K | |
| 72100 | <1% | 927 | $140K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 154 | $125K |
| 86140 | <1% | 13,515 | $121K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,434 | $117K |
| 70486 | <1% | 1,657 | $113K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,363 | $107K |
| 87040 | <1% | 6,030 | $99K | |
| 82570 | <1% | 4,901 | $97K | |
| 87340 | <1% | 4,637 | $96K | |
| 82272 | <1% | 315 | $95K | |
| 85610 | <1% | 4,659 | $94K | |
| 99173 | <1% | 660 | $93K | |
| 84145 | <1% | 3,356 | $92K | |
| 86780 | <1% | 9,491 | $88K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 9,988 | $82K |
| 93000 | <1% | 5,783 | $82K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 176 | $81K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 533 | $80K |
| 88142 | <1% | 1,490 | $80K | |
| 73560 | <1% | 383 | $76K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,698 | $73K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 749 | $72K |
| 92552 | <1% | 99 | $71K | |
| 74018 | <1% | 794 | $66K | |
| 73080 | <1% | 297 | $65K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 728 | $62K |
| 76642 | <1% | 420 | $61K | |
| 87400 | <1% | 166 | $54K | |
| 76770 | <1% | 326 | $54K | |
| 92002 | <1% | 71 | $51K | |
| 85370 | <1% | 2,881 | $51K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 958 | $50K |
| 97161 | <1% | 2,012 | $50K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 225 | $46K |
| 83880 | <1% | 2,928 | $42K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 66 | $41K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 2,893 | $40K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,195 | $39K |
| 99285 | Emergency room visit (most serious) | <1% | 3,498 | $38K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 63 | $38K |
| 92587 | <1% | 855 | $36K | |
| 82150 | <1% | 397 | $36K | |
| 92555 | <1% | 121 | $36K | |
| 97162 | <1% | 1,307 | $36K | |
| 96381 | <1% | 44 | $34K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 283 | $34K |
| 82951 | <1% | 93 | $31K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 734 | $31K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 82 | $30K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 41 | $28K |
| J3490 | Unclassified drugs | <1% | 111 | $28K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 465 | $27K |
| 11982 | <1% | 112 | $27K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,673 | $27K |
| 71250 | <1% | 176 | $27K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 29 | $27K |
| 84550 | <1% | 1,263 | $27K | |
| 84153 | <1% | 213 | $26K | |
| 84484 | <1% | 3,911 | $24K | |
| 86885 | <1% | 5,113 | $23K | |
| 83735 | <1% | 4,330 | $20K | |
| 92551 | <1% | 33 | $19K | |
| 91320 | <1% | 31 | $19K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 482 | $18K |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 90 | $17K |
| 83690 | <1% | 5,294 | $17K | |
| 73502 | <1% | 126 | $16K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 25 | $16K |
| 92523 | <1% | 124 | $16K | |
| 86038 | <1% | 215 | $15K | |
| 82542 | <1% | 4,137 | $15K | |
| 82550 | <1% | 1,007 | $14K | |
| 84156 | <1% | 2,277 | $14K | |
| 83655 | <1% | 26 | $13K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 14 | $13K |
| 83021 | <1% | 108 | $13K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 18 | $12K |
| 82565 | <1% | 853 | $11K | |
| J2560 | Injection, phenobarbital sodium, up to 120 mg | <1% | 131 | $11K |
| 87420 | <1% | 127 | $9K | |
| 10060 | <1% | 675 | $9K | |
| 83540 | <1% | 3,775 | $9K | |
| 97163 | <1% | 42 | $9K | |
| 82157 | <1% | 13 | $8K | |
| 84480 | <1% | 26 | $8K | |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 13 | $8K |
| 87517 | <1% | 36 | $8K | |
| 99243 | <1% | 18 | $8K | |
| 97010 | <1% | 12 | $8K | |
| 84075 | <1% | 73 | $7K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 140 | $7K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 32 | $7K |
| 11981 | <1% | 66 | $7K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 14 | $7K |
| 82731 | <1% | 75 | $7K | |
| 73120 | <1% | 57 | $7K | |
| 59025 | Fetal non-stress test | <1% | 2,759 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 34,202 | $6K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 652 | $6K |
| 97602 | <1% | 42 | $6K | |
| 86431 | <1% | 302 | $6K | |
| 86708 | <1% | 14 | $5K | |
| 97167 | <1% | 26 | $5K | |
| G0378 | Hospital observation service, per hour | <1% | 51 | $5K |
| 82677 | <1% | 1,037 | $5K | |
| 90746 | <1% | 30 | $5K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 54 | $5K |
| V5020 | Conformity evaluation | <1% | 13 | $4K |
| 87507 | <1% | 13 | $4K | |
| 73600 | <1% | 30 | $4K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 902 | $3K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 28 | $3K |
| 87556 | <1% | 15 | $3K | |
| 82784 | <1% | 12 | $3K | |
| 86900 | <1% | 5,033 | $3K | |
| 86706 | <1% | 276 | $3K | |
| 83605 | <1% | 3,937 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 135 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,008 | $3K |
| 20610 | <1% | 33 | $3K | |
| 92015 | Determination of refractive state | <1% | 106 | $2K |
| 86765 | <1% | 2,911 | $2K | |
| 87205 | <1% | 647 | $2K | |
| 76818 | <1% | 15 | $2K | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 3,140 | $2K |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 225 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 230 | $2K |
| 82746 | <1% | 1,921 | $2K | |
| 58300 | <1% | 85 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 28 | $1K |
| 99234 | <1% | 2,837 | $1K | |
| 92504 | <1% | 539 | $1K | |
| G8981 | Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 244 | $1K |
| G8982 | Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 258 | $1K |
| 85008 | <1% | 302 | $1K | |
| 97166 | <1% | 14 | $1K | |
| 84132 | <1% | 13 | $945.00 | |
| 87536 | <1% | 12 | $862.00 | |
| 12001 | <1% | 72 | $710.00 | |
| 12011 | <1% | 12 | $710.00 | |
| 74022 | <1% | 58 | $682.00 | |
| 92591 | <1% | 13 | $682.00 | |
| 86200 | <1% | 70 | $653.00 | |
| 86901 | 0% | 5,032 | $0.00 | |
| 90480 | 0% | 469 | $0.00 | |
| 85660 | 0% | 84 | $0.00 | |
| 80329 | 0% | 3,345 | $0.00 | |
| 83550 | 0% | 3,292 | $0.00 | |
| 99235 | 0% | 674 | $0.00 | |
| 90474 | 0% | 1,764 | $0.00 | |
| 83789 | 0% | 5,932 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 188 | $0.00 |
| 80320 | 0% | 6,181 | $0.00 | |
| 82803 | 0% | 150 | $0.00 | |
| 96376 | 0% | 769 | $0.00 | |
| 85379 | 0% | 64 | $0.00 | |
| 70498 | 0% | 54 | $0.00 | |
| 0134A | 0% | 140 | $0.00 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 22 | $0.00 |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 33 | $0.00 |
| 87081 | 0% | 12 | $0.00 | |
| 83498 | 0% | 13 | $0.00 | |
| 81374 | 0% | 17 | $0.00 | |
| 74019 | 0% | 52 | $0.00 | |
| 99403 | 0% | 12 | $0.00 | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 0% | 379 | $0.00 |
| 84100 | 0% | 242 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 49 | $0.00 |
| 84520 | 0% | 675 | $0.00 | |
| 86336 | 0% | 1,024 | $0.00 | |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 242 | $0.00 |
| 96367 | 0% | 28 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 667 | $0.00 |
| 51701 | 0% | 17 | $0.00 | |
| 99222 | Initial hospital care, per day, moderate complexity | 0% | 13 | $0.00 |
| 86235 | 0% | 19 | $0.00 | |
| 0124A | 0% | 162 | $0.00 | |
| 98960 | 0% | 32 | $0.00 | |
| 87075 | 0% | 167 | $0.00 | |
| 0071A | 0% | 76 | $0.00 | |
| J2315 | Injection, naltrexone, depot form, 1 mg | 0% | 13 | $0.00 |
| 91322 | 0% | 47 | $0.00 | |
| 29125 | 0% | 16 | $0.00 | |
| 82977 | 0% | 12 | $0.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 18 | $0.00 |
| 87653 | 0% | 13 | $0.00 | |
| 90473 | 0% | 14 | $0.00 | |
| 99221 | 0% | 15 | $0.00 | |
| 86003 | 0% | 12 | $0.00 | |
| 91321 | 0% | 15 | $0.00 | |
| 87150 | 0% | 12 | $0.00 | |
| 10061 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWINKELMAN, DANIEL (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Yukon-Kuskokwim Health Corporation | Bethel, AK | $96.17M |
| Yukon Kuskokwim Health Corp | Bethel, AK | $29.52M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.